Skip Navigation

European Heart Journal 1996 17(10):1565-1571;
Copyright © 1996 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Valenti, R.
Right arrow Articles by Kappenberger, L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Valenti, R.
Right arrow Articles by Kappenberger, L.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 The European Society of Cardiology

Impact of the implantable cardioverter-defibrillator on rehospitalizations

R. Valenti, J. Schlapfer, M. Fromer, A. Fischer* and L. Kappenberger

Division of Cardiology and Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland
*Division of Cardiac Surgery, Centre Hospitalier Universitaire Vaudois Lausanne, Switzerland

revised 19 January 1996; accepted 29 January 1996.

Prof. Lukas Kappenberger, Division of Cardiology, Centre Hospitalier Universitaire Vaudois, CH 1011 L.ausanne, Switzerland.

Abstract

Patients who survive out-of-hospital ventricular tachycardia or ventricular fibrillation are at risk of sudden cardiac death and often return to hospital after initial discharge. The frequency and duration of readmittance to hospital are not well known. Thus, the purpose of this study was to evaluate the impact of the implantable cardioverter defibrillator on frequency and duration of hospitalizations.

METHODS: Between 1989 and 1993, 38 consecutive patients who had drug-refractory ventricular tachyarrhythmias were selected for the study. A total of 38 patients were implanted with the implantable cardioverter-defibrillator in accordance with the guidelines of the European Society of Cardiology. This analysis includes 35 of the 38 patients (92%). All hospitalizations which occurred one year before and one year after were studied. Clinical information for all patients was obtained by consulting medical records and by interviewing personal general practitioners.

RESULTS: The annual number of hospitalizations before and after implantation of the implantable cardioverter defibrillator was, respectively, 3·28 ± 2 hospitalizations/patient/year and 0·88 ± 1·23 hospitalizations/patient/year (P<0·05). Before implantation of the implantable cardioverter-defibrillator, patients were hospitalized a mean of 32·94 plusmn; 24·18 days/patient/year and after, 9·31 ± 32·14 days/patient/year (P<0·05). The number of hospitalizations for cardiac reasons decreased by 90%. Before implantation, the most frequent cause was ventricular tachyarrhythmia (47 hospitalizations for ventricular tachycardia and eight for ventricular fibrillation), while after implantation, it was as a result of the shock from the implantable cardioverter defibrillator (II hospitalizations). The number of hospitalizations for non-cardiac reasons were similar in the two time periods. Of the 35 patients, 26 (74%) had at least one appropriate successful ventricular tachycardia interrupted by the implantable cardioverter-defibrillator, while 17 patients (49%) had their ventricular fibrillation terminated. There is a significant difference in the rate of hospitalizations to intensive care units (ICU) between the two periods. Before implantation, 30% of hospital days were spent in the ICU, with 3% after.

CONCLUSIONS: This study documents that the implantable cardioverter-defibrillator not only reduces the frequency and duration of hospital stays, but reduces admissions to the more expensive units in hospital. Taking into account the reduction in hospitalizations, the payback period for the implantation of an implantable cardioverter-defibrillator is 19 months.

(Eur Heart J 1996; 17: 1565–1571)

Key Words: Hospitalizations • hospital stay • implantation • cost analysis


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
Eur Heart JHome page
A.J Camm and S Nisam
The Utilization of the Implantable Defibrillator--a European Enigma
Eur. Heart J., December 2, 2000; 21(24): 1998 - 2004.
[PDF]


Home page
Eur Heart JHome page
T. Korte, W. Jung, G. Ostermann, C. Wolpert, S. Spehl, B. Esmailzadeh, and B. Luderitz
Hospital readmission after transvenous cardioverter/defibrillator implantation. A single centre study
Eur. Heart J., July 2, 2000; 21(14): 1186 - 1191.
[Abstract] [PDF]


Home page
Eur Heart JHome page
P.R. Roberts, T.R. Betts, and J.M. Morgan
Cost effectiveness of the implantable cardioverter defibrillator
Eur. Heart J., May 1, 2000; 21(9): 712 - 719.
[PDF]


Home page
CirculationHome page
M. S. Stanton and G. K. Bell
Economic Outcomes of Implantable Cardioverter-Defibrillators
Circulation, March 7, 2000; 101(9): 1067 - 1074.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.